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ABSTRACT OF THE THESIS
SERUM TRANSTHYRETIN IN HEM ODIALYSIS PATIENTS: RELATIONSHIP TO
NUTRITIONAL STATUS
by
Annmarie Duggan
Florida International University, 1997
Miami, Florida
Professor Fatrma G. Huffman, Major Professor
The validity of serum transthyretin as a nutrition assessment parameter in
hemodialysis patients was investigated. Fifty-one subjects (39% male and 61 % female;
53% black, 28% white, 12% Hispanic, 7% Other) receiving hemodialysis for 30 24
months (mean SD) and a total of 36 26 months of renal replacement therapy were followed
for six months. Serum transthyretin, albumin, BUN, creatinine, cholesterol, normalized
protein catabolic rate (nPCR), KT/V, weight and 24 hour urine analysis were determined
monthly. Etiologies of end stage renal disease were diabetic nephropathy (37%),
hypertensive nephrosclerosis (37%). glomerulonephritis (12%), polycystic kidney disease
(4%), lupus nephritis (4%), other causes (6%). A significant correlation was found between
transthyretin and creatinine, albumin and loss of dry weight (p<0.05). Transthyretin levels
<30 mg/dl were found to correlate with urine outputs > 240 cc/24 hours, predialysis BUN
< 50 mg/dl and nPCR <O.8 gm/kg/day (p<0.05). Transthyretin levels were higher in non-
diabetics for all six months (significant in two/six months). No significant correlation was
found between transthyretin and age, gender, race, months of hemodialysis, cholesterol or
KT/V. Transthyretin levels may be used as an additional assessment parameter to identify
hemodialysis patients who may benefit from nutritional intervention.
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INTRODUCTION
Despite advances in the provision of renal replacement therapy, there still remains a high
morbidity and mortality rate in hemodialysis patients. Increasing evidence links poor nutritional
status to the increased morbidity and mortality observed in the hemodialysis patient (1, 2).
Nutritional assessment is important to identify the patient with or at risk for malnutrition. Low
levels of serum albumin and cholesterol have been shown to be strong predictors of mortality in
the dialysis population (2). These biochemical markers reflect long term malnutrition and may
not accurately reflect early signs of inadequate protein and energy intake (1, 3). A low serum
level of transthyretin (formerly known as prealbumin) has also been shown to be an independent
predictor of morbidity (4) and mortality (4-6) in the hemodialysis patient. Transthyretin levels are
an early indicator of adequate or inadequate nutritional intake (7), an index for the provision of
adequate nutritional support (7, 8) and a marker for visceral protein anabolism (8). Since serum
transthyretin has a half life of two days and responds rapidly to increased or decreased
nutritional intake (7), it has been proposed as a short term marker of nutritional adequacy in the
hemodialysis patient.
The protein catabolic rate (PCR) is a common parameter used to evaluate recent nutritional
intake in hemodialysis patients. PCR is derived through urea kinetic modeling from the urea
generation rate and expressed as normalized PCR (nPCR) in relation to body weight. If the
patient is in a steady state, PCR is a reflection of dietary protein intake, thereby serving as an
early marker of inadequate protein intake (9). In a recent study examining the relationship of
serum levels of transthyretin with dietary protein intake in hemodialysis patients, a correlation
was found between low transthyretin levels (<30 mg/dl) and lower protein catabolic rates (nPCR)
<1.2/gm/kg (10). This finding merits further investigation and additional research to validate the
correlation between low transthyretin and low protein catabolic rate.
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JUSTIFICATION
A very limited amount of information has been published regarding the use of serum
transthyretin as an early marker of malnutrition in the hemodialysis population. Even less
information is available regarding the correlation of PCR with serum transthyretin levels. If low
serum levels of transthyretin correlate with inadequate dietary protein as evidenced by low
protein catabolic rates, serum transthyretin would serve as an easily accessible early indicator
for aggressive nutrition intervention. The routine drawing of serum transthyretin levels in
hemodialysis patients for nutritional assessment purposes would be justified by the above
findings.
PURPOSE OF RESEARCH
The purpose of this study was to confirm the use of serum transthyretin as a valid early
marker of poor nutritional status in the hemodialysis patient and to validate the correlation of low
serum transthyretin levels with established nutrition assessment parameters and lower protein
catabolic rates.
HYPOTHESIS TESTED
Primary:
1. Serum transthyretin levels less than 30 mg/dl correlate with normalized protein catabolic rates
less than 1.0 gm/kg body weight/day.
2. Low serum transthyretin levels correlate with low predialysis blood urea nitrogen.
3. Transthyretin levels increase/decrease prior to changes in serum albumin levels and
cholesterol levels.
Secondary:
1. Serum transthyretin levels less than 30 mg/dl are indicative of inadequate energy intake as
evidenced by a decrease in dry weight and body mass index.
2. There is no difference in transthyretin levels based on age, race, length of time on dialysis, or
diabetic status.
3
REVIEW OF THE LITERATURE
The relationship between malnutrition and increased morbidity and mortality has been well
established in the hemodialysis population (1, 2). The nutrition markers, cholesterol and serum
albumin, have been shown to have a strong predictive value of outcome in hemodialysis
patients (2, 11). Goldwasser et a. found that single measurements of albumin and cholesterol
are independent predictors of survival for at least two years in both recently diagnosed and long-
standing dialysis patients and these markers remain predictive even in patients receiving
adequate dialysis (12). These biochemical markers reflect long term malnutrition and may not
accurately identify the early signs of inadequate protein and energy intake (1, 3). A valid short
term indicator of malnutrition is needed for early identification of the hemodialysis patient at risk.
Transthyretin Levels and Nutritional Status
Serum transthyretin, also known as thyroxine-binding prealbumin or prealbumin, has been
proposed as an early indicator of nutritional status in hemodialysis patients (4, 6, 13, 14).
Transthyretin, with a molecular weight of 54,000, is synthesized primarily in the liver and
circulates as a stable and symmetrical tetramer composed of four tryptophan rich identical
subunits of 127 amino acids each (15, 16). Transthyretin serves as a transport protein for
thyroxine (T4) and a carrier protein for retinol binding protein and therefore vitamin A.
Transthyretin levels in serum increase or decrease in relation to the adequacy of protein or
energy intake. Transthyretin decreases rapidly in response to lowered energy or protein intake,
even when protein intake is inadequate for a little as three days (15).
Transthyretin may have advantages over the use of either albumin or transferrin as a short
term marker of nutritional adequacy. Transthyretin has a short half life of two days, high
tryptophan content, high proportion of essential to nonessential amino acids and small pool size.
It is therefore thought to be a better indicator of visceral protein status and positive nitrogen
balance than albumin or transferrin (17). Concentrations of transthyretin also are not
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significantly influenced by fluctuations in hydration status which is of clinical significance for
hemodialysis patients (15).
Transthyretin Levels in Chronic Renal Failure
Elevated levels of transthyretin have been observed in patients with chronic renal failure (18).
Previously it was thought that the elevated transthyretin levels seen in hemodialysis versus
healthy controls discounted its use as a nutritional marker in this population. Cano et al (18)
concluded that the elevated transthyretin levels seen in chronic renal failure were related to
alterations in the degradation of prealbumin-retinol binding protein complex. During uremia, the
increase in plasma retinol binding protein is responsible for an increase in the prealbumin
fraction bound to the prealbumin-retinol-binding protein-retinol complex. The subsequent
reduction of free prealbumin may account for the decrease in prealbumin breakdown and the
increase in total plasma transthyretin (19). If adjustment is made for an altered physiological
range, transthyretin concentrations correlate with nutrition status of patients with a stable degree
of renal failure, such as that found in hemodialysis patients (4, 18). Also, if a trend in the
direction of change is noted, despite the elevated levels seen in renal failure, the changes are
likely to reflect alterations in nutritional status and nitrogen balance (15).
In studies involving hemodialysis patients, transthyretin levels have been found to correlate
with other established nutrition assessment parameters, further supporting its use as a nutrition
indicator in this population (4-6, 20). Jacob et at (20) confirmed the value of transthyretin as a
marker of under nutrition through its correlation with both triceps skin fold thickness and midarm
muscle circumference. Cano et at (4) in the statistical selection of nutrition parameters in
hemodialyzed patients demonstrated that a serum transthyretin < 0.30 gram /liter correlated with
body weight, arm muscle circumference, triceps skin fold, albumin and creatinine (4). Avram et
at (5) also found that serum transthyretin correlated strongly with other baseline biochemical
markers - albumin, creatinine and cholesterol. Cano et at (10) in their study of the relation of
serum transthyretin levels and protein intake in hemodialysis patients, found that a serum
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transthyretin level < 0.30 g/liter corresponded to a protein catabolic rate (nPCR) of <1.2 9/kg/day
with a lack of correlation seen between these two variables when nPCR exceeded 1.4 g/kg/day.
Vehe et al (21) in a study of nutrition support in infected patients with chronic renal failure found
that transthyretin correlated significantly with cumulative intakes of both protein and energy.
Transthyretin Level- A Predictor of Morbidity and Mortality
Transthyretin levels have also been demonstrated to have predictive value for morbidity and
mortality in hemodialysis and peritoneal dialysis patients. Avram et al. (5) in a seven year
prospective study, found that patients with serum transthyretin levels of 30 mg/dl or above had a
survival rate of over 80% at 40 months, versus patients with baseline values lower than 30
mg/dl, who had only 40% survival rate. It was concluded that a low level of serum transthyretin
was an important and independent predictor of mortality risk for hemodialysis and peritoneal
dialysis patients followed up to 40 months. Cano et al. (4) demonstrated that low levels of serum
transthyretin but not albumin or anthropometrics were associated with increased mortality in
hemodialysis patients. A serum transthyretin less than 0.30 g/liter predicted both infection and
mortality risks with high sensitivity and specificity.
Goldwasser et a. (6) concluded that transthyretin was actually a stronger independent
correlate of mortality risk than albumin concentration. Transthyretin concentration may be more
reflective of a distinct aspect of mortality risk than albumin, or albumin concentration may be
more influenced by factors unrelated to mortality risk. The increased predictive power was also
attributed to the shorter half-life of serum transthyretin, permitting rapid changes in its
concentration in response to under nutrition or catabolism. Sreedhara et al. (22) found that there
was a higher relative risk of death in hemodialysis patients with a serum transthyretin <30 mg/dl.
A single measurement of transthyretin was found to predict patient survival for up to five years.
Jacob et al. (20) found that transthyretin levels of 0.30 g/liter were fairly sensitive in identifying
wasted patients as well as those with a history of recent infection, yet IGF-1 had a higher
predictive value. Jacob et al (20) also found that patients with a history of infection in the prior
six months had lower intakes of protein and calories as well as lower serum concentrations of
transthyretin and IGF-1 when compared with the infection-free patients.
These findings support that a low serum transthyretin level in hemodialysis patients is
correlated with increased morbidity and mortality, lower protein catabolic rate and is a valid
marker of visceral protein status if altered physiological ranges are taken into account.
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METHODOLOGY
Study Design
This was a prospective, cohort, correlation, nonintervention study utilizing convenience
sampling. The study was approved by the Florida International University Institutional Review
Board prior to implementation.
Subjects and Setting
Patients were selected from a population of seventy seven patients receiving hemodialysis
treatments at Complete Dialysis Care, Inc., a free standing outpatient dialysis clinic in Coral
Springs, Florida. A convenient sample of fifty one patients were enrolled in June 1996 after
meeting the following eligibility criteria: (1) have received hemodialysis treatments for greater
than 3 months, (2) receive thrice weekly hemodialysis treatments, (3) absence of impaired
hepatic function, (4) absence of chronic infection, inflammatory syndromes or infections in the
three months prior to the study, (5) not taking corticosteroids, (6) willingness to participate in the
study as evidenced by signing of an Informed Consent. Subjects were followed for six months.
Those who developed infection within the six month study period were excluded from the study.
Forty three patients completed the six month study period. Four patients discontinued due to
infection, one due to noncompliance with treatments, one expired, one underwent kidney
transplantation and one transferred to another facility.
Demographic and Clinical Data Collection
Demographic data included age, gender and race. Clinical data included:
(1) etiology of end stage renal disease obtained from the HCFA 2728 form in the patients' chart,
(2) total months on hemodialysis determined by calculating the number of months between the
first outpatient dialysis treatment and the first month of data collection, (3) diabetic condition as
defined as the history of a diagnosis of non-insulin dependent or insulin dependent diabetes
mellitus, (4) measured height, (5) post-dialysis weight was recorded on the day of the monthly
lab collection for each month of the study. Body Mass Index (Quetelet's Index) was determined
by weight in kg divided by height in meters squared.
Biochemical Data Collection
Biochemical data was obtained from routine monthly midweek blood specimens for six
consecutive months. Normalized protein catabolic rate and KTV were calculated for the last
three consecutive months of the study period utilizing three blood urea nitrogen levels (BUN).
Pre and post dialysis BUN was drawn after the first treatment of the week (Monday) to calculate
nPCR and KTIV. The dialysis machine blood pump flow was lowered to 100 cc/minute for exactly
one minute prior to drawing the post dialysis BUN specimen.
Prior to the second treatment of the week (Wednesday), serum albumin, transthyretin,
creatinine, cholesterol and predialysis BUN levels were obtained. Serum was analyzed at REN
Laboratories, Fort Lauderdale, Florida by the following methods: blood urea nitrogen - urease,
albumin - bromcresol green (BOG) dye binding, cholesterol - enzymatic hydrolysis with
cholesterol ester hydrolase, cholesterol oxidase and peroxidase, creatinine - Jaffe method.
Serum transthyretin was determined by nephelemetry. The nPCR was calculated utilizing the
Mistebar Urea Kinetics Analysis Program for the PC (Mistebar Computer Consultants, Inc., Las
Cruces, NM).
Urine specimens were obtained for all patients who had urine outputs >240 cc in twenty four
hours. The twenty four hour urine volume was recorded and urine was analyzed for urine urea
nitrogen (method - urease enzyme) and total urinary protein (method - benzethonium chloride).
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Statistical Analysis
Population frequencies were calculated for race, gender, etiology of end stage renal disease
and diabetic status. The mean and standard deviations were determined for age, months of
hemodialysis, total months of renal replacement therapy, dry weight, body mass index, weight
change over six months, transthyretin, albumin, cholesterol, BUN, KTN, and nPCR. Cholesterol
levels for patients taking cholesterol lowering medications were eliminated from all statistical
analysis.
Correlation data is expressed as Pearson correlation coefficients (r) unless otherwise
indicated. Correlations were examined between transthyretin levels and nPCR, age, gender,
race, diabetic status, dry weight, body mass index, albumin, cholesterol, creatinine, BUN, KTN,
urinary protein and dry weight loss. Fishers Exact Test, Student's t-test and Chi-squared test
were utilized for categorical data analysis utilizing a cutoff value of transthyretin less than 30
mg/dl as per Cano et al. (4,10).
Calculations were performed using the Statistical Package for the Social Sciences Version
4.1 software.
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RESULTS
Demographic data is included in Table 1. The mean age of the population was 60 17 years.
The patients had received 30 24 months (mean SD) of hemodialysis therapy and a total of 36
26 months (mean SD) of renal replacement therapy. Forty three percent of the subjects
had diabetes. Sixty one percent were female, thirty nine percent were male. The ethnic
distribution was as follows: 28% white, 53% black, 12% Hispanic, 7% Other. The etiologies of
end stage renal disease are listed in Table 2 and include diabetic nephropathy (37%),
hypertensive nephrosclerosis (37%), glomerulonephritis (12%), polycystic kidney disease (4%),
lupus nephritis (4%). There was no significant correlation between serum transthyretin levels
and age, race, gender, months of hemodialysis, length of time receiving renal replacement
therapy or etiology of end stage renal disease.
The mean and standard deviations of study parameters of the subjects for the six month
study period are given in Table 3. The distribution of the mean transthyretin level over six
months is illustrated in Figure 1. The overall mean transthyretin level for all subjects in six
months was 32.4-6.8 mg/dl. This is above the acceptable level in the hemodialysis population
of 30 mg/dl. Sixty-four percent of the subjects had a mean transthyretin level above 30 mg/dl
and thirty-six percent had mean levels less than 30 mg/dl for the six month study period (Figure
1).
Pearson correlation coefficients for the relationship of transthyretin with other nutrition
parameters are listed in Table 4. There was a statistically significant positive correlation
between serum transthyretin and serum albumin (r= 0.524, p= 0.000), serum creatinine
(r=0.464, p= 0.000) and loss of dry body weight (r= 0.339, p= 0.032). Categoucal data analysis
is listed in Table 5. There was a significant and positive correlation, utilizing Fishers Exact Test,
between transthyretin levels <30 mg/dl and predialysis BUN levels <50 mg/dl (p= 0.017), urine
output >240 cc in twenty four hours (p= 0.039) and with nPCR < 0.8 gm/kg/day (p< 0.05).
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No statistically significant correlations were found between transthyretin <30 mg/dl and serum
cholesterol <150 mg/dl or KT/V<1.2.
Figure 2. depicts the mean albumin levels and the mean transthyretin levels for each month
of the study period. The mean transthyretin level dropped below the acceptable range of 30
mg/dl in month 4 without any noticeable change in the mean
albumin level. Also, thirty-five percent of the subjects (18/51) had a six month mean
transthyretin level <30 mg/dl despite a six month mean albumin level >3.5 gm/dl. In addition (not
depicted in a table), there was a positive association between changes in levels of serum
albumin and changes in levels of transthyretin between each month of the study period (Pearson
correlation coefficient range= 0.284- 0.621). As the mean transthyretin increased, the mean
albumin increased and as transthyretin decreased, the mean albumin decreased. This was
statistically significant for four out of the five monthly intervals (range p= 0.000 - p= 0.024);
A comparison of transthyretin levels (Student's t-test) in diabetics versus non-diabetics is
shown in Figure 3. Transthyretin levels were higher in non-diabetics than diabetics for all six
months, yet this was only statistically significant (p< 0.05) in two out of the six months. A
comparison of other nutrition parameters between diabetics and non-diabetics is shown in Table
6. Mean creatinine levels (p= 0.02) were significantly lower in diabetics versus non-diabetics and
BMI was significantly higher in diabetics (p= 0.034). Mean predialysis BUN and nPCR were
lower in diabetics, although this was not statistically significant. Females (p= 0.018) had
significantly higher BMI values than males. Mean creatinine levels (p<.001), BMI (p=.018) and
body weights (p=.002) were significantly lower in whites than blacks (Students t-test). Mean
creatinine levels were also found to be significantly lower in the nine patients who urinated >240
cc in 24 hours (p<.001). There was no significant difference in creatinine levels or transthyretin
levels between men and women.
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DISCUSSION
This study confirms the usefulness of transthyretin as a marker of nutritional adequacy in
hemodialysis patients. The strong correlation of serum transthyretin with other nutrition
assessment parameters, serum albumin and creatinine, is in agreement with previous studies of
transthyretin by other investigators (4-6, 22). The correlation of serum transthyretin with serum
creatinine and albumin also supports its significance as a prognostic indicator. Creatinine, which
reflects lean body mass, and serum albumin, which reflects visceral protein stores, have both
been found to be inversely correlated with mortality in the hemodialysis population (2). A single
measurement of transthyretin less than 30 mg/dl has been found to be an independent predictor
of mortality in the hemodialysis population (4-6, 22).
The hypothesis that low levels of serum transthyretin would correlate with low predialysis
BUN was accepted. The correlation in the present study between transthyretin <30 mg/dl with
predialysis BUN <50 mg/dl and nPCR <0.8 gm/kg/day supports that transthyretin levels drop in
response to inadequate protein intake. The hypothesis that transthyretin < 30 mg/dl would
correlate with nPCR <1.0 gm/kg/day was rejected. A statistically significant correlation of
transthyretin with nPCR was only found at nPCR < 0.8 gm/kg/day in this cohort, whereas Cano et
al. (10) found a correlation of transthyretin < 30 mg/dl and nPCR levels of <1.2 gm/kg/day. This
may have been due to the use of a smaller sample size in the present study and the finding that
only 14/51 (28%) of subjects had a three month mean nPCR level >1.2 gm/kg/day. Fifty percent
of the subjects had a mean nPCR between 0.8-1.2 gm/kg/day. The mean nPCR < 0.8
gm/kg/day, found in twenty two percent of the subjects, was indicative of inadequate dietary
protein intake to maintain visceral protein stores, as evidenced by the lower transthyretin levels.
In hemodialysis patients nPCR values between 1.0 -1.4 gm/kg/day are desirable to maintain lean
body mass (1). The National Cooperative Dialysis Study found that an nPCR >1 gm/kg/day and
a BUN >50 mg/dl were associated with lower morbidity (23). Based on these findings, serum
transthyretin may not replace nPCR as a short term indicator of nutritional adequacy, as it may
22
miss patients with nPCR values between 0.8-1.0 gm/kg/day, yet it provides an additional marker
for the need for nutrition intervention.
The hypothesis that serum transthyretin levels <30 mg/dl would be indicative of inadequate
energy intake as evidenced by loss of dry weight was accepted. The correlation between serum
transthyretin and loss of dry body weight supports that serum transthyretin may be a marker of
inadequate energy intake in patients who are receiving hemodialysis treatments. These findings
are in agreement with Vehe et al. (21) where transthyretin correlated significantly with
cumulative intakes of both protein and energy, in chronic renal failure patients receiving nutrition
support. Transthyretin has been found to correlate with other markers of body mass such as the
midarm muscle circumference (4, 13, 20) and triceps skinfold thickness (4, 20).
A correlation was not found between inadequate dialysis and low transthyretin. This may
have been due to an adequate three month mean KTN of 1.47 0.28 and that only two patients
(4%) had a three month mean KTN of less than 1.2. Clearly there were not enough patients
receiving inadequate dialysis to identify a statistically significant finding. It is recognized that the
results involving KTN and nPCR are also limited by the use of single-pool kinetic modeling.
Since transthyretin has a much shorter half life than albumin, we sought to evaluate whether
transthyretin levels would rise or fall prior to changes in albumin levels. The hypothesis that
transthyretin levels would increase or decrease prior to changes in albumin levels was rejected
as a positive association was found between changes in levels of serum albumin and changes in
levels of transthyretin. This may have been due to the monthly interval in which specimens were
drawn. Since serum levels were only obtained on a monthly basis, changes in transthyretin
levels (half-life 1-2 days) that may have occurred before changes in albumin levels (half-life 21
days) were not detected. The strong correlation between albumin and transthyretin levels and
the correlation between changes in monthly transthyretin correlating with changes in albumin
levels, could be interpreted as negating the advantages of measuring transthyretin as an
additional nutrition indicator. Yet, the finding that thirty five percent of the subjects had six
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month mean transthyretin levels < 30 mg/dl despite a mean albumin level> 3.5 gmldl justifies
the use of transthyretin as a marker for patients requiring nutrition intervention that may not have
been identified based on serum albumin levels alone. The early identification of patients with
poor nutritional intake, through the measurement of serum transthyretin, would allow for early
nutrition intervention thereby preventing a further decline in nutritional status and its associated
higher morbidity and mortality. As patients with conditions that may influence transthyretin levels
(such as the development of infection) were excluded from the study, the changes in
transthyretin that occurred without changes in albumin, may be attributed to changes in
nutritional intake of dietary protein or energy rather than an acute phase response.
Caution must be used in interpreting transthyretin levels in subjects who urinate >240 cc per
day. These subjects were found to have significantly lower transthyretin levels. Subjects who
urinated >240 cc per day also had significantly lower creatinine levels, yet no significant
difference in serum albumin levels. A statistically significant inverse correlation was not found
between total milligrams of urinary protein excreted per day and serum transthyretin levels.
Findings of this study are limited by the small percentage of the cohort (9/51 or 18%) who still
urinated >240 cc per day. Therefore, more research is needed to clarify the interpretation of
serum transthyretin as a nutritional marker in subjects who still have residual renal function and
proteinuria.
The hypothesis that there would be no difference in transthyretin levels based on age, race
and length of time on dialysis was accepted. In this patient cohort, the inverse correlation
between age and transthyretin which was previously demonstrated by Sreedhara et at (22) was
not found. The positive correlation between transthyretin with total cholesterol found by other
investigators (5, 6) was not confirmed in this cohort. This may have been due to a limited sample
size in the present study. Transthyretin levels were lower in diabetics which is in agreement with
Sreedhara et al. (22) therefore the hypothesis that there would be no difference in transthyretin
levels between diabetics and nondiabetics was rejected. Yet, the lower transthyretin level in
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diabetics versus non-diabetics was only statistically significant in two out of the six months
(Figure 3). Diabetics also had lower serum creatinine levels despite significantly higher body
mass indexes. This may have been due to an excess of adiposity with a decrease in lean body
mass in the diabetics, although body composition measurements were not performed to confirm
this. As the presence of diabetes and the presence of low serum transthyretin are both
independent predictors of mortality (5, 22), diabetic subjects who have low serum transthyretin
levels represent a group who may benefit from prompt intervention to improve nutritional status.
The above findings are limited by the use of a convenient sample, a limited sample size and
a short study period (6 months), assumption that single pool urea kinetic modeling accurately
determines KTV and nPCR, and accuracy of the 24 hour urine collection by the subject. Despite
these limitations, the findings support that despite the elevated levels of serum transthyretin in
chronic renal failure, serum transthyretin is a useful nutrition assessment parameter after
adjustment for altered physiological range.
SUMMARY, CONCLUSIONS, RECOMMENDATIONS
Measuring serial serum transthyretin levels in hemodialysis patients is a reliable method for
identifying patients at nutritional risk, as well as patients at higher morbidity and mortality risk.
Serum transthyretin may serve as a marker for those in need of nutritional intervention, who may
not have been identified based on serum albumin alone. Future research is needed to determine
the response of serum transthyretin to nutritional supplementation in the hemodialysis setting.
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Appendix A
INFORMED CONSENT
SERUM TRANSTHYRETIN (PREALBUMIN) IN HEMODIALYSIS PATIENTS: RELATIONSHIP
TO NUTRITIONAL STATUS ANDY OTEIN CATABOLLC RATE
YOU ARE ASKED TO READ THE FOLLOWING FORM TO MAKE SURE THAT YOUCOMPLETELY UNDERSTAND WHAT WILL HAPPEN IF YOU AGREE TO TAKE PART INTHIS RESEARCH STUDY, SIGNING THIS FORM MEANS THAT THE STUDY HAS BEENEXPLAINED TO YOU AND THAT YOU GIVE YOUR PERMISSION TO TAKE PART. THEFEDERAL GOVERNMENT REQUIRES YOUR APPROVAL IN WRITING BEFORE YOU TAKEPART IN ANY RESEARCH STUDY. IT IS IMPORTANT THAT YOU KNOW WHAT WILL TAKEPLACE AND WHAT RISKS ARE INVOLVED BEFORE YOU DECIDE WHETHER OR NOT TOTAKE PART IN THIS STUDY.
1. RESEARCILRURPSENDURALQN
The research project entitled "Serum transthyretin (prealbumin) in hemodialysispatients: relationship to nutritional status and protein catabolic rate" is to be
conducted by Annmarie Duggan R.D., L.D. and Fatma G. Huffman Ph.D., R.D. asPrincipal Investigators from Florida International University. This research will last
approximately 3 months starting Summer 1996 and there will be approximately70 participants in the total sample.
The purpose of this research is to determine if serum transthyretin is an early
marker of adequacy of nutritional status and if there isa correlation betweenlow levels of this protein and a low protein catabolic rate.
2.PROCEDUlRES
You will continue to have your usual monthly lab work drawn. Your albumin,
transthyretin, cholesterol and blood urea nitrogen levels will be recorded as
study data. For three consecutive months you will also have a pre dialysis blood
urea nitrogen and a transthyretin level drawn on the Friday after your monthly
bloodwork. During the entire three month study period, only 10 milliliters of
additional blood will be drawn. You will be asked to collect a 24 hour urine
specimen if you urinate more than 240 cc (8 ounces) per day.
3.RISKS OR DISCOMFORTS
There are no known risks or discomforts involved in your participation in this
research study.
4. BENEFITS 10OU
Although it may not be a directly benefit you to participate, this study will
contribute knowledge about adequate nutritional assessment for hemodialysis
patients and could result in the early identification for your need for nutrition
intervention. You will continue to receive your routine monthly nutrition
counseling as usual.
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5. COST TO YOU FOR TAKING PART IN RESEARCH STUDY
There will be no cost to you for taking part in this study.
6. PAYMENT FOTAKING PART IN _RESEARCHSTUDY
You will not be paid for taking part in this research study.
7.CONFIDENTI ALIY
All information which refers to, or can be identified with you, will remain
confidential to the extent permitted by law. No information will be revealed
about you or your part in this study, without your permission or the permission ofyour legally authorized representative, except that which may be necessary for
the Research Committee to satisfy their legal responsibility for review of theproject.
. C_ AI E_
Financial compensation for research-related injury of loss of wages is not
available; however, necessary emergency medical care will be provided
without cost, if not covered by a third parly payer.
9. WHQCO-NAC LORASWERS
If you desire further information about this research contact Fatma HuffmanPh.D. at 305-348-2878 at Florida International University or Annmarie Duggan, R.D.
at 954-345-2446.
10. PARTCIPATION&-V-OLUNTARY
Your participation in this study is voluntary. If you wish, you may choose not totake part in this study. You may withdraw your consent and discontinue
participation in this research project at any time without any negative
consequences.
11. I HAVE READ, UNDERSTOOD, AND RECEIVED A COPY OF THIS INFORMED
CONSENT FORM AND AGREE TO PARTICIPATE IN THIS STUDY.
Principal Investigator Date Participant Date
Telephone No. Witness Date
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Appendix B
PERMISO DE APROVACION
LE HEMOS PEDIDO QUE LEA EL SIGUIENTE FORMULARIG PARA ASEGURARNOS DE
QUE UTSTED ENTIENDA CONPETAMENTE LO QUE VA A OCCURIR SI USTED ACEPTA
PARTICIPAR EN ESTE ESTUDIO DE INVESTiGACIONES. AL FIRMIAR ESTE
DOCUMENTO, NOS INDICA QUE A USTED SE LE HA ESPLICADO EL MOTIVA DE LA
INVESTiGACION Y QUE USTED NOS HA DADO EL PERMISO PARA SU
PARTICIPACION. EL GOBIEVNO FEDERAL REQUIERE QUE USTED NOS DE SU
APROVACION P02 ESCRITO ANTES DE QUE USTED PUEDA PARTICIPAR EN EL
PROGRAMA. ES iMPORTANTE QUE USTED SEPA LO QUE VA OCCURIR Y TODOS LOS
RIESGOS QUE VAN ENVOLUCRADOS ANTES DE QUE USTED DECJDA SI VA A
PARTICIPAR 0 NO EN ESTE ESTUDJO.
. JEIVOELESIU OYDRACIO
El estudio titulado "Suero transthyretina en pacientos de dialisis- relacionado con
pa nutricion y el indice de catabolismo de proteina" sera conducido por
Annmarie Duggan R.D., LD. y Fatma G. Huffman Ph.D., RD. coma principiantes
investigadoras de la Universidad Internacional de Ia Florida. Este estudio durara
aproximadamente tres meses comensando en 1996 y habran
aproximadamente 70 participantes en el estudlo. El objetivo de este estudio es
para determinar si transthyretina es un indicador prematuro de una
atimentacion adecuada y si hay una corretacion el estatus nutricionat entr
niveles vajos de esta proteina y el indice catabolismo de proteina.
2.PROCEDMIENTOS
A usted le van hacer sus trabajos de laboratoric mensuatmente como siempre.
Su atbumina, transthyretina, catesterot y urea sanguinea seran anotados como
datos del estudio. Par 3 meses consecutivos, le tomarar, su nivel de urea
sanguinea para calcular el indice de (un indicador de su proteina ingerida)p
Sera requerido que usted obetnga de orina cada 24 hrs. En el caso de que
pueda orinar mas de 8 onza at dia.
3. RIESGOS EANCOMODJDADES
No hay riesgos conocidos ni incomodidades envolucrados con su participacion
en esta investigacion.
4. BENEFICIOS PARA USTED
Aunque su participacion no Io beneficie directamente, esta investigacion sera
muy constructiva para poder determinar una mejor evaluacion alimenticia y al
mismo tiempo padremos identificar si usted necisita alteraciones en su dieta.
Usted tendra sus spsiones consultorias con la dietista mensualmente como se
acostumbra.
Iniciales del paciente _
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S.COSTO PARA PARTICIPAR EN EL ESTUDIO
No habra costo alguno por su participacion en este estudlo. Su copaboracion
en este projecto, tendra un valor muy importante par la el futuro de todos los
pacientes que se encuentrar en dialisis.
6 RECOMPESAROR PAICIPACO El -ES TESTUDO
No habra recompensa monetaria par su participacion en el estudia.
7 CONEIDENCIA tDAD
Toda Ia informacion que se refiera a usted a que puedo ser identificada con
usted semantendra confidencial segun permeitne las leyes de la fha. Ninguna
inforracion sobre usted o sobre su paricipacion sera revelada sin su permiso a
el permiso de su abogado solamente sera la dibulgada informacion que sera
utilizada par el comite de Investigacion. Toda Ia informacion sera utilizada
dentro de tfos los ambitos legales que pemite Ia ley.
ESEAS
Si usted deasea mas informacion sobre este estudia investigatiorie comaniquese
con Fatma G. Huffman Ph.D. al 305-348-2878 a Annmarie Duggan RD. al 954-
345-2446,
_._PARTICIACQN ES VOLUNTARIA
Su participacion en este estudia es voluntaria. Si usted desea, puede decidir no
participar en este estudio usted puede anular su permiso de aprovacian y
descantinuar su participacion en este projecto a cualquier hora sin alguna
consecuencia negativa sabre su tratamiento rutinario de dahisic.
10. YO HE LEIDO, ENTENDIDO, Y RECIBIDO UNA COPIA DE ESTE FORMULARIC DE
APROVACION Y ESTOY DE ACUERDO A PARTICIPAR EN ESTE ESTUDIO.
Investigador Principal Fecha Participante Fecha
No. de TelefonI Testigo Fecha
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